CBDV

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid and a propyl analog of CBD, meaning it has a shortened 3-carbon side chain compared to CBD's 5-carbon chain. This seemingly minor structural difference gives CBDV a distinct pharmacological profile with particularly strong anticonvulsant and anti-nausea properties. CBDV is found in highest concentrations in indica landrace strains from Northwest India, Nepal, and Pakistan, as well as in certain hemp cultivars specifically bred for high CBDV content.

CBDV has generated significant pharmaceutical interest, particularly from GW Pharmaceuticals (now Jazz Pharmaceuticals), which has conducted multiple clinical trials investigating CBDV for epilepsy and autism spectrum disorder (ASD). The autism trials are especially noteworthy — CBDV was granted orphan drug designation by the European Medicines Agency for the treatment of Rett syndrome, a rare neurodevelopmental disorder on the autism spectrum. While the clinical results have been mixed, the pharmaceutical industry's willingness to invest in full-scale clinical trials underscores the perceived potential of this cannabinoid.

Preclinical research has identified CBDV as a potent modulator of TRP channels, particularly TRPV1, TRPV2, and TRPA1, which are involved in pain perception, inflammation, and neuronal excitability. CBDV also interacts with the diacylglycerol lipase (DAGL) enzyme involved in endocannabinoid biosynthesis, suggesting a mechanism for modulating endocannabinoid tone distinct from CBD's FAAH inhibition. These diverse mechanisms position CBDV as a uniquely versatile minor cannabinoid with multiple potential therapeutic applications.